A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study [0.03%]
小样本轻度认知障碍患者使用 triflusal 治疗的随机双盲对照研究：TRIMCI 研究
Teresa Gómez-Isla,Rafael Blesa,Merce Boada et al.
Teresa Gómez-Isla et al.
Background: Amnestic mild cognitive impairment represents, in many cases, the earliest clinical phases of Alzheimer disease. Anti-inflammatory agents have epidemiologic support as drugs potentially beneficial in Alzheimer...
Randomized Controlled Trial
Alzheimer disease and associated disorders. 2008 Jan-Mar;22(1):21-9. DOI:10.1097/WAD.0b013e3181611024 2008
Lissy Jarvik,Asenath LaRue,Deborah Blacker et al.
Lissy Jarvik et al.
Children of persons with Alzheimer disease (AD), as a group, face an increased risk of developing AD. Many of them, throughout their adult lives, seek input on how to reduce their chances of one day suffering their parent's fate. We examine...
Paul S Aisen
Paul S Aisen
Alzheimer disease research: have we forgotten the cerebrovascular circulation? [0.03%]
阿尔茨海默病研究：我们是否忽视了脑血管循环？
Gustavo C Román
Gustavo C Román
Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals [0.03%]
R-氟吡洛芬短期治疗在健康老年人中安全性和耐受性、药代动力学及阿蛋白水平的研究
Douglas R Galasko,Neil Graff-Radford,Susanne May et al.
Douglas R Galasko et al.
To evaluate the safety and tolerability and pharmacokinetic properties of R-flurbiprofen (Tarenflurbil) in normal elderly individuals and to determine the effect of the drug on amyloid beta 42 (Abeta42) levels, we conducted a double-blind, ...
Qingli Shi,Gary E Gibson
Qingli Shi
Alzheimer disease (AD) is defined by progressive impairments in memory and cognition and by the presence of extracellular neuritic plaques and intracellular neurofibrillary tangles. However, oxidative stress and impaired mitochondrial funct...
M-Marsel Mesulam
M-Marsel Mesulam
The diagnosis of primary progressive aphasia (PPA) is made in any patient in whom a language impairment (aphasia), caused by a neurodegenerative disease (progressive), constitutes the most salient aspect of the clinical picture (primary). T...
Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies [0.03%]
frontal lobe痴呆的治疗：目前的症状治疗方法及最近基因、生化和神经影像学研究的意义
Adam L Boxer,Bradley F Boeve
Adam L Boxer
Frontotemporal dementia (FTD) is a common cause of dementia that encompasses 3 clinical subtypes: a behavioral/dysexecutive (frontal) variant and 2 variants with prominent language impairments. There are currently no Food and Drug Administr...
Rate of cognitive change measured by neuropsychologic test performance in 3 distinct dementia syndromes [0.03%]
三种不同痴呆综合征中认知变化速度的神经心理测试评估指标
Alissa H Wicklund,Alfred Rademaker,Nancy Johnson et al.
Alissa H Wicklund et al.
Progressive decline in cognition is a hallmark feature of dementia, and the rate and profile of cognitive decline has been well characterized in Alzheimer disease (AD). Less is known about decline in cognition over time in other forms of de...